BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

127 related articles for article (PubMed ID: 36625399)

  • 1. Advances in the clinical management of high-risk Wilms tumors.
    Ortiz MV; Koenig C; Armstrong AE; Brok J; de Camargo B; Mavinkurve-Groothuis AMC; Herrera TBV; Venkatramani R; Woods AD; Dome JS; Spreafico F
    Pediatr Blood Cancer; 2023 Mar; 70(3):e30153. PubMed ID: 36625399
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Advances in the clinical management of high-risk Wilms tumors.
    Ortiz MV; Koenig C; Armstrong AE; Brok J; de Camargo B; Mavinkurve-Groothuis AMC; Herrera TBV; Venkatramani R; Woods AD; Dome JS; Spreafico F
    Pediatr Blood Cancer; 2023 May; 70 Suppl 2(Suppl 2):e30342. PubMed ID: 37096797
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Survival in nephroblastoma treated according to the trial and study SIOP-9/GPOH with respect to relapse and morbidity.
    Weirich A; Ludwig R; Graf N; Abel U; Leuschner I; Vujanic GM; Mehls O; Boos J; Beck J; Royer-Pokora B; Voûte PA
    Ann Oncol; 2004 May; 15(5):808-20. PubMed ID: 15111352
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Unmet needs for relapsed or refractory Wilms tumour: Mapping the molecular features, exploring organoids and designing early phase trials - A collaborative SIOP-RTSG, COG and ITCC session at the first SIOPE meeting.
    Brok J; Mavinkurve-Groothuis AMC; Drost J; Perotti D; Geller JI; Walz AL; Geoerger B; Pasqualini C; Verschuur A; Polanco A; Jones KP; van den Heuvel-Eibrink M; Graf N; Spreafico F
    Eur J Cancer; 2021 Feb; 144():113-122. PubMed ID: 33341445
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinical impact of histologic subtypes in localized non-anaplastic nephroblastoma treated according to the trial and study SIOP-9/GPOH.
    Weirich A; Leuschner I; Harms D; Vujanic GM; Tröger J; Abel U; Graf N; Schmidt D; Ludwig R; Voûte PA
    Ann Oncol; 2001 Mar; 12(3):311-9. PubMed ID: 11332141
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Results of the SIOP 93-01/GPOH trial and study for the treatment of patients with unilateral nonmetastatic Wilms Tumor.
    Reinhard H; Semler O; Bürger D; Bode U; Flentje M; Göbel U; Gutjahr P; Leuschner I; Maass E; Niggli F; Scheel-Walter HG; Stöckle M; Thüroff JW; Tröger J; Weirich A; von Schweinitz D; Zoubek A; Graf N
    Klin Padiatr; 2004; 216(3):132-40. PubMed ID: 15175957
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pharmacotherapeutic Management of Wilms Tumor: An Update.
    Oostveen RM; Pritchard-Jones K
    Paediatr Drugs; 2019 Feb; 21(1):1-13. PubMed ID: 30604241
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Treatment of relapsed Wilms tumour (WT) patients: experience with topotecan. A report from the SIOP Renal Tumour Study Group (RTSG).
    Mavinkurve-Groothuis AM; van den Heuvel-Eibrink MM; Tytgat GA; van Tinteren H; Vujanic G; Pritchard-Jones KL; Howell L; Graf N; Bergeron C; Acha T; Catania S; Spreafico F
    Pediatr Blood Cancer; 2015 Apr; 62(4):598-602. PubMed ID: 25546733
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The prognostic significance of blastemal predominant histology in initially resected Wilms' tumors: a report from the Study Group for Pediatric Solid Tumors in the Kyushu Area, Japan.
    Kinoshita Y; Suminoe A; Inada H; Yagi M; Yanai F; Zaizen Y; Nishi M; Inomata Y; Kawakami K; Matsufuji H; Suenobu S; Handa N; Kohashi K; Oda Y; Hara T; Taguchi T
    J Pediatr Surg; 2012 Dec; 47(12):2205-9. PubMed ID: 23217877
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Wilms tumour: prognostic factors, staging, therapy and late effects.
    Kaste SC; Dome JS; Babyn PS; Graf NM; Grundy P; Godzinski J; Levitt GA; Jenkinson H
    Pediatr Radiol; 2008 Jan; 38(1):2-17. PubMed ID: 18026723
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Outcome of patients with stage IV high-risk Wilms tumour treated according to the SIOP2001 protocol: A report of the SIOP Renal Tumour Study Group.
    Pasqualini C; Furtwängler R; van Tinteren H; Teixeira RAP; Acha T; Howell L; Vujanic G; Godzinski J; Melchior P; Smets AM; Coulomb-L'Hermine A; Brisse H; Pritchard-Jones K; Bergeron C; de Camargo B; van den Heuvel-Eibrink MM; Graf N; Verschuur AC
    Eur J Cancer; 2020 Mar; 128():38-46. PubMed ID: 32109849
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Relapse of unilateral favorable histology Wilms' tumor: significant clinicopathological factors.
    Aoba T; Urushihara N; Fukumoto K; Furuta S; Fukuzawa H; Mitsunaga M; Watanabe K; Yamoto M; Miyake H; Koyama M; Iwabuchi H; Koike J; Tatsunami S; Wakisaka M; Kitagawa H
    J Pediatr Surg; 2012 Dec; 47(12):2210-5. PubMed ID: 23217878
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Complete necrosis induced by preoperative chemotherapy in Wilms tumor as an indicator of low risk: report of the international society of paediatric oncology (SIOP) nephroblastoma trial and study 9.
    Boccon-Gibod L; Rey A; Sandstedt B; Delemarre J; Harms D; Vujanic G; De Kraker J; Weirich A; Tournade MF
    Med Pediatr Oncol; 2000 Mar; 34(3):183-90. PubMed ID: 10696124
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Blastemal predominant type Wilms tumor in Japan: Japan Children's Cancer Group.
    Koshinaga T; Takimoto T; Okita H; Tanaka Y; Inoue E; Oue T; Nozaki M; Tsuchiya K; Haruta M; Kaneko Y; Fukuzawa M
    Pediatr Int; 2019 Apr; 61(4):351-357. PubMed ID: 30786111
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A 23-year experience with malignant renal tumors in infancy and childhood.
    Tröbs RB; Hänsel M; Friedrich T; Bennek J
    Eur J Pediatr Surg; 2001 Apr; 11(2):92-8. PubMed ID: 11371043
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Characteristics and outcome of stage II and III non-anaplastic Wilms' tumour treated according to the SIOP trial and study 93-01.
    Graf N; van Tinteren H; Bergeron C; Pein F; van den Heuvel-Eibrink MM; Sandstedt B; Schenk JP; Godzinski J; Oldenburger F; Furtwängler R; de Kraker J
    Eur J Cancer; 2012 Nov; 48(17):3240-8. PubMed ID: 22795263
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinical and biologic significance of nuclear unrest in Wilms tumor.
    Hill DA; Shear TD; Liu T; Billups CA; Singh PK; Dome JS
    Cancer; 2003 May; 97(9):2318-26. PubMed ID: 12712489
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Expression and prognostic value of Wilms' tumor 1 and early growth response 1 proteins in nephroblastoma.
    Ghanem MA; Van der Kwast TH; Den Hollander JC; Sudaryo MK; Oomen MH; Noordzij MA; Van den Heuvel MM; Nassef SM; Nijman RM; Van Steenbrugge GJ
    Clin Cancer Res; 2000 Nov; 6(11):4265-71. PubMed ID: 11106242
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Response to letter commenting on "Outcome of localised blastemal-type Wilms tumour patients treated according to intensified treatment in the SIOP WT 2001 protocol, a report of the SIOP Renal Tumour Study Group (SIOP-RTSG)".
    ; van den Heuvel-Eibrink MM; Pritchard-Jones K; van Tinteren H; Graf N
    Eur J Cancer; 2015 May; 51(8):995-6. PubMed ID: 25840668
    [No Abstract]   [Full Text] [Related]  

  • 20. Association between long interspersed nuclear element-1 methylation levels and relapse in Wilms tumors.
    de Sá Pereira BM; Montalvão-de-Azevedo R; Faria PA; de Paula Silva N; Nicolau-Neto P; Maschietto M; de Camargo B; Soares Lima SC
    Clin Epigenetics; 2017; 9():128. PubMed ID: 29255497
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.